$2.79
+0.14 (+5.28%)
Open$2.66
Previous Close$2.65
Day High$2.84
Day Low$2.44
52W High$13.15
52W Low$2.59
Volume—
Avg Volume2.07M
Market Cap277.46M
P/E Ratio—
EPS$-2.17
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+2,262.4% upside
Current
$2.79
$2.79
Target
$65.91
$65.91
$44.11
$65.91 avg
$67.85
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 85.03M | 357.40M | 350.63M |
| Net Income | -172,829,526 | 35.24M | 44.72M |
| Profit Margin | -203.3% | 9.9% | 12.8% |
| EBITDA | -180,248,298 | 65.64M | 71.27M |
| Free Cash Flow | — | 46.75M | 30.69M |
| Rev Growth | +299.7% | +16.3% | -1.3% |
| Debt/Equity | 0.84 | 0.42 | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |